Liver Diseases  >>  Victrelis (boceprevir)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Victrelis (boceprevir) / Roche, Merck (MSD)
NCT00708500 / 2007-005151-42: Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Checkmark APASL 2014: RESPOND-2
Mar 2014 - Mar 2014: APASL 2014: RESPOND-2
Checkmark AASLD 2013: SPRINT-2 & RESPOND-2 HEOR
Oct 2013 - Oct 2013: AASLD 2013: SPRINT-2 & RESPOND-2 HEOR
Checkmark SPRINT-2, RESPOND-2
More
Completed
3
404
NA
Boceprevir (SCH 503034), Pegylated interferon alfa-2b (SCH 54031), PegIntron, PEG2b, Ribavirin (SCH 18908), Rebetol, RBV, Boceprevir placebo
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
04/10
04/10
SPRINT-2, NCT00705432 / 2007-005508-42: Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)

Checkmark EASL 2014: SPRINT-2
Mar 2014 - Mar 2014: EASL 2014: SPRINT-2
Checkmark AASLD 2013: SPRINT-2 & RESPOND-2 HEOR
Oct 2013 - Oct 2013: AASLD 2013: SPRINT-2 & RESPOND-2 HEOR
Checkmark SPRINT-2, RESPOND-2
More
Completed
3
1472
NA
Peginterferon alfa-2b (PEG), PegIntron, PEG, SCH 54031, Ribavirin (RBV), Rebetol, RBV, SCH 18908, Placebo, Boceprevir, SCH 503034, Victrelis
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
05/10
05/10
NCT00845065 / 2008-004760-39: Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)

Checkmark P3 data
Mar 2012 - Mar 2012: P3 data
Completed
3
202
NA
Boceprevir, SCH 503034, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, SCH 18908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
10/10
10/10
NCT01446250: Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Terminated
3
8
US
Alisporivir, DEB025, Boceprevir, Victrelis®, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Debiopharm International SA
Hepatitis C
05/13
05/13
LeeG3, NCT01585584: Triple-Therapy in Patients With HCV Genotype 3 Who Previously Failed Treatment

Completed
3
11
Canada
Boceprevir, VICTRELIS™, boceprevir capsules, 200 mg, Hepatitis C Virus (HCV) Protease Inhibitor
University of Calgary, Merck Sharp & Dohme LLC
Hepatitis C
12/14
07/15
NCT01390844: Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Completed
3
282
NA
Boceprevir (BOC), SCH 503034, Victrelis, Placebo to boceprevir, Peginterferon alfa-2b (PEG), PegIntron, SCH 054031, Redipen, Ribavirin (RBV), Rebetol, SCH 018908, Cross-Over Boceprevir Treatment
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
06/15
06/15
MK-3034-107, NCT01945294: Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1

Completed
3
257
NA
Boceprevir, MK-3034, Peg-interferon alfa-2b, PegIntron, Ribavirin, Rebetol
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
08/15
11/15
NCT02204475: Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Withdrawn
3
0
US
Grazoprevir/Elbasvir, Boceprevir, PegIntron, Pegylated Interferon, Ribavarin
Merck Sharp & Dohme LLC
Hepatitis C
06/16
09/16
BOLERO-CB, NCT02060058: Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy

Completed
3
12
RoW
Stop trial intervention for boceprevir, PEG-IFN and RBV, Stop trial intervention for arm A, Stop trial intervention for arm B, Stop trial intervention for arm C
Kaohsiung Medical University Chung-Ho Memorial Hospital, National Taiwan University Hospital
Hepatitis C, Chronic
09/16
09/16
NCT01641666: Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Withdrawn
3
0
RoW
Boceprevir, SCH 503034, Peginterferon Alfa-2b 1.5 mcg/kg/week, Pegintron®, Rebetol®, Ribavirin
Merck Sharp & Dohme LLC
Chronic Hepatitis C
09/16
09/16
NCT00689390 / 2006-006529-25: Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Checkmark CROI 2014
Mar 2014 - Mar 2014: CROI 2014
Terminated
2/3
1954
NA
Boceprevir, SCH 503034, Narlaprevir, SCH 900518, Peginterferon alfa-2b, PEG-Intron®, SCH 054031, Ribavirin, Rebetol®, Blood/Plasma Collection
Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hepacivirus
10/14
10/14

Download Options